Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Multicenter, Single-Blind, Randomized, Warfarin-Controlled Trial of Edoxaban in Patients With Chronic Thromboembolic Pulmonary Hypertension: KABUKI Trial.
Hosokawa K, Watanabe H, Taniguchi Y, Ikeda N, Inami T, Yasuda S, Murohara T, Hatano M, Tamura Y, Yamashita J, Tatsumi K, Tsujino I, Kobayakawa Y, Adachi S, Yaoita N, Minatsuki S, Todaka K, Fukuda K, Tsutsui H, Abe K; KABUKI Investigators. Hosokawa K, et al. Among authors: hatano m. Circulation. 2024 Jan 30;149(5):406-409. doi: 10.1161/CIRCULATIONAHA.123.067528. Epub 2023 Nov 13. Circulation. 2024. PMID: 37956127 Free PMC article. Clinical Trial. No abstract available.
Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients--association between non-responders and chronic kidney disease.
Imamura T, Kinugawa K, Shiga T, Kato N, Muraoka H, Minatsuki S, Inaba T, Maki H, Hatano M, Yao A, Kyo S, Nagai R. Imamura T, et al. Among authors: hatano m. Circ J. 2013;77(2):397-404. doi: 10.1253/circj.cj-12-0971. Epub 2012 Nov 3. Circ J. 2013. PMID: 23131721 Free article. Clinical Trial.
Trend of clinical outcome and surrogate markers during titration of β-blocker in heart failure patients with reduced ejection fraction: relevance of achieved heart rate and β-blocker dose.
Kato N, Kinugawa K, Imamura T, Muraoka H, Minatsuki S, Inaba T, Maki H, Shiga T, Hatano M, Yao A, Komuro I, Nagai R. Kato N, et al. Among authors: hatano m. Circ J. 2013;77(4):1001-8. doi: 10.1253/circj.cj-12-1241. Epub 2012 Dec 19. Circ J. 2013. PMID: 23258250 Free article. Clinical Trial.
Successful treatment of hemodynamic compromise caused by antibody-mediated and cellular rejection in a recipient 12 years after heart transplantation.
Imamura T, Kinugawa K, Kato N, Kagami Y, Endo M, Kaneko N, Minatsuki S, Muraoka H, Inaba T, Maki H, Hatano M, Doi K, Yao A, Takazawa Y, Ono M, Kyo S, Komuro I. Imamura T, et al. Among authors: hatano m. Int Heart J. 2013;54(5):328-31. doi: 10.1536/ihj.54.328. Int Heart J. 2013. PMID: 24097224 Free article.
Tolvaptan can improve clinical course in responders.
Imamura T, Kinugawa K, Minatsuki S, Muraoka H, Kato N, Inaba T, Maki H, Hatano M, Yao A, Komuro I. Imamura T, et al. Among authors: hatano m. Int Heart J. 2013;54(6):377-81. doi: 10.1536/ihj.54.377. Int Heart J. 2013. PMID: 24309447 Free article.
Urine sodium excretion after tolvaptan administration is dependent upon baseline serum sodium levels: a possible explanation for the improvement of hyponatremia with scarce chance of hypernatremia by a vasopressin receptor antagonist.
Imamura T, Kinugawa K, Minatsuki S, Muraoka H, Kato N, Inaba T, Maki H, Hatano M, Yao A, Komuro I. Imamura T, et al. Among authors: hatano m. Int Heart J. 2014;55(2):131-7. doi: 10.1536/ihj.13-221. Epub 2014 Mar 14. Int Heart J. 2014. PMID: 24632953 Free article.
1,213 results